In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $72.31, marking a -2.24% move from the previous day.

Arc Institute, Gladstone Institutes, and University of California, San Francisco, scientists have developed an epigenetic ...

Precision genome editing is revolutionizing the treatment of rare genetic disorders, offering hope through customized therapies while raising ethical and medical concerns.

Gene editing, led by CRISPR, is expanding rapidly beyond medical applications, offering new opportunities across various biotech industries. Technological breakthroughs are fueling acceleration and ...

Scientists developed an epigenetic editing platform using CRISPRoff and CRISPRon to reprogram human T cells. Unlike ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

Arc Institute, Gladstone Institutes, and University of California, San Francisco, scientists have developed an epigenetic ...

Also! In honor of World CRISPR Day (yesterday, but close enough), we have a very special 50% discount rate if you sign up for ...

LinkedIn co-founder Reid Hoffman warns that Silicon Valley's software obsession is limiting AI opportunities in healthcare ...

Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced ...

Despite the mechanisms that made it a “biologically plausible” candidate, the study found that participants who took the drug didn’t have better functional capacity or respiratory function than those ...